Long-term betaxolol therapy in glaucoma patients with pulmonary disease
- PMID: 3400758
- DOI: 10.1016/0002-9394(88)90828-8
Long-term betaxolol therapy in glaucoma patients with pulmonary disease
Abstract
We evaluated the use of topically administered betaxolol 0.5% in 101 glaucoma patients (47 men and 54 women) who had chronic obstructive pulmonary disease, asthma, or timolol-induced bronchoconstriction. Betaxolol 0.5% was administered twice daily and patients were reexamined at three-month intervals for up to two years. In addition to measurement of intraocular pressure, pulmonary function tests were obtained before therapy (baseline), two or three weeks after initiating betaxolol therapy, and at yearly intervals. Before treatment with betaxolol, the mean ratio of forced expiratory volumes in one second (FEV1) to forced vital capacity (FVC) was 66.3% (n = 101). After two weeks of betaxolol treatment, mean FEV1/FVC ratio was 66.2% (n = 101). After one year of betaxolol therapy, mean FEV1/FVC ratio was 60.1% (n = 24), and after two years it was 54.4% (n = 5). Nine patients developed symptoms that may have been associated with betaxolol treatment and were withdrawn from the study. Five of these patients developed symptomatic pulmonary obstruction between one and 554 days after initiating betaxolol treatment. Topically administered betaxolol was well tolerated by most glaucoma patients with concomitant pulmonary disease.
Similar articles
-
Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.Drugs. 1990 Jul;40(1):75-90. doi: 10.2165/00003495-199040010-00005. Drugs. 1990. PMID: 2202584 Review.
-
Betaxolol in patients with glaucoma and asthma.Am J Ophthalmol. 1986 May 15;101(5):531-4. doi: 10.1016/0002-9394(86)90941-4. Am J Ophthalmol. 1986. PMID: 3706457
-
Betaxolol in chronic obstructive pulmonary disease.J Ocul Pharmacol. 1987 Summer;3(2):171-6. doi: 10.1089/jop.1987.3.171. J Ocul Pharmacol. 1987. PMID: 2903205
-
Betaxolol eye drops as a safe medication to lower intraocular pressure.Aust N Z J Ophthalmol. 1987 May;15(2):125-9. doi: 10.1111/j.1442-9071.1987.tb00057.x. Aust N Z J Ophthalmol. 1987. PMID: 2887181 Clinical Trial.
-
Comparison of ophthalmic beta-blocking agents.Clin Pharm. 1987 Jun;6(6):451-63. Clin Pharm. 1987. PMID: 2891463 Review.
Cited by
-
Assessment of bronchial effects following topical administration of butylamino-phenoxy-propanol-acetate, an oculoselective beta-adrenoceptor blocker in asthmatic subjects.Br J Clin Pharmacol. 1992 Aug;34(2):122-9. doi: 10.1111/j.1365-2125.1992.tb04120.x. Br J Clin Pharmacol. 1992. PMID: 1358158 Free PMC article. Clinical Trial.
-
Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.Drugs. 1990 Jul;40(1):75-90. doi: 10.2165/00003495-199040010-00005. Drugs. 1990. PMID: 2202584 Review.
-
Do selective topical beta antagonists for glaucoma have respiratory side effects?Br J Ophthalmol. 2004 Feb;88(2):196-8. doi: 10.1136/bjo.2003.017715. Br J Ophthalmol. 2004. PMID: 14736772 Free PMC article.
-
Marine-Steroid Derivative 5α-Androst-3β, 5α, 6β-triol Protects Retinal Ganglion Cells from Ischemia⁻Reperfusion Injury by Activating Nrf2 Pathway.Mar Drugs. 2019 May 5;17(5):267. doi: 10.3390/md17050267. Mar Drugs. 2019. PMID: 31060323 Free PMC article.
-
Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.Drugs Aging. 1992 May-Jun;2(3):208-21. doi: 10.2165/00002512-199202030-00005. Drugs Aging. 1992. PMID: 1351412 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
